News Related to Atara Biotherapeutics

Related coverage linked through entity extraction aliases.

Class Action Lawsuits Filed Against Atara Biotherapeutics and Inovio Pharmaceuticals

Apr 02, 2026

Class action lawsuits allege securities violations by Atara Biotherapeutics and Inovio Pharmaceuticals related to FDA submissions. Atara faces claims over manufacturing issues with its tabelecleucel BLA, while Inovio is accused of misleading statements about INO-3107 regulatory timelines and manufacturing deficiencies.

Atara Biotherapeutics Schedules FDA Meeting on Tabelecleucel Application

Mar 12, 2026

Atara Biotherapeutics announced a Type A meeting with the FDA to discuss the Complete Response Letter for tabelecleucel's Biologics License Application, held by partner Pierre Fabre Pharmaceuticals.